Table 1.
Baseline demographic characteristics in the safety population of participants who received the third dose
| 1·5 μg group | 3 μg group | 6 μg group | Placebo group | |
|---|---|---|---|---|
| Cohort 1a-14d-2m (a third dose at month 2 after the second dose) | ||||
| Number of participants | NA | 55 | 58 | 26 |
| Age, years | NA | 45·2 (9·1) | 44·7 (8·6) | 44·3 (8·6) |
| Male | NA | 29 (53%) | 20 (34%) | 10 (38%) |
| Female | NA | 26 (47%) | 38 (66%) | 16 (62%) |
| Cohort 1b-14d-8m (a third dose at month 8 after the second dose) | ||||
| Number of participants | NA | 55 | 56 | 30 |
| Age, years | NA | 40·4 (10·3) | 42·4 (8·8) | 44·8 (6·9) |
| Male | NA | 24 (44%) | 27 (48%) | 12 (40%) |
| Female | NA | 31 (56%) | 29 (52%) | 18 (60%) |
| Cohort 2a-28d-2m (a third dose at month 2 after the second dose) | ||||
| Number of participants | NA | 54 | 50 | 26 |
| Age, years | NA | 42·5 (8·6) | 40·7 (9·4) | 44·0 (7·7) |
| Male | NA | 34 (63%) | 26 (52%) | 14 (54%) |
| Female | NA | 20 (37%) | 24 (48%) | 12 (46%) |
| Cohort 2b-28d-8m (a third dose at month 8 after the second dose) | ||||
| Number of participants | NA | 52 | 50 | 28 |
| Age, years | NA | 44·3 (9·5) | 43·1 (9·9) | 45·7 (9·7) |
| Male | NA | 23 (44%) | 26 (52%) | 11 (39%) |
| Female | NA | 29 (56%) | 24 (48%) | 17 (61%) |
| Cohort 3-28d-8m (a third dose at month 8 after the second dose) | ||||
| Number of participants | 85 | 90 | 81 | 47 |
| Age, years | 66·3 (4·4) | 66·4 (4·4) | 66·3 (4·4) | 67·1 (4·7) |
| Male | 41 (48%) | 44 (49%) | 37 (46%) | 27 (57%) |
| Female | 44 (52%) | 46 (51%) | 44 (54%) | 20 (43%) |
Data are n (%) or mean (SD). NA=not applicable.